Compare AbbVie Inc (ABBV) vs Trade Desk Inc (TTD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Trade Desk Inc — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while Trade Desk Inc trades at $19.12 (market cap $9.02B). The key difference: AbbVie Inc is far larger — about 49.9× Trade Desk Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.
| ABBV | TTD | |
|---|---|---|
Market Cap | $449.91B | $9.02B |
Sector | Health | Technology |
52-Week High | $261.07 | $89.76 |
52-Week Low | $184.85 | $17.33 |
Enterprise Value | $513.38B | $8.03B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
The Trade Desk (TTD) trades at $19.18, up 0.42% with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company maintains strong profitability with 77.83% gross margins and 14.57% net income margin, though Q1 2026 earnings missed expectations. Revenue growth has been consistent, reaching $2.9B in 2025, while analyst sentiment remains divided with a $25.46 consensus target representing 33% upside potential.
TTD presents a compelling value opportunity with reasonable valuations (P/E 21.94, P/S 3.17) and strong cash flow generation, but faces near-term headwinds from recent earnings miss and competitive pressures in digital advertising. The stock's 86% decline from 2024 highs creates potential for recovery if execution improves, though investor caution is warranted given mixed analyst ratings and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
